Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckRobert L. Ferris, Maura L. Gillison, George R. Blumenschein et al.|New England Journal of Medicine|2016Cited by 5.1k
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion CohortLaura Q.M. Chow, Tanguy Y. Seiwert, Robert I. Haddad et al.|Journal of Clinical Oncology|2016Cited by 859
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expressionRobert L. Ferris, Maura L. Gillison, Lisa Licitra et al.|Oral Oncology|2018Cited by 802
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialNancy Y. Lee, Ezra E.W. Cohen, Robert L. Ferris et al.|The Lancet Oncology|2021Cited by 618
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012Ranee Mehra, Robert I. Haddad, Tanguy Y. Seiwert et al.|British Journal of Cancer|2018Cited by 457